Tilda Research builds autonomous AI agents purpose-built for clinical trial workflows — automating documentation, data extraction, and compliance tasks that traditionally require manual effort. The tech stack is infrastructure-heavy (Kubernetes, Terraform, CloudFormation across AWS/GCP/Azure) with robust CI/CD and observability (GitHub Actions, GitLab CI, Datadog, Prometheus), indicating a complex operational environment. Current hiring skews senior engineering and product roles, with active focus on test automation frameworks and QMS systems — a pattern that aligns with a compliance-first business selling into regulated healthcare.
Tilda Research develops AI agents that automate the operational backbone of clinical trials. The platform targets CROs, sponsors, and research organizations managing trial workflows, replacing human-intensive tasks in data management, regulatory documentation, and compliance monitoring. Founded in 2019 and based in Tustin, California, the company operates at 51–200 employees with engineering and product centered in North America and expansion hiring in India. Projects span automation frameworks, CI/CD optimization, document classification, metadata extraction, and quality management system improvements — reflecting both internal maturation and customer-facing feature velocity.
Python, Go, TypeScript, and React for application code; AWS, GCP, and Azure for cloud infrastructure; Kubernetes and Docker for orchestration; GitHub Actions, GitLab CI, and Jenkins for CI/CD; Datadog, Prometheus, and Grafana for monitoring.
AI-driven feature design (document classification, metadata extraction, workflow automation), CI/CD pipeline optimization, automated testing strategies, quality management system improvements, and vendor qualification frameworks.
Other companies in the same industry, closest in size